news.google.com· FierceBiotech·· 1 day agoPickScore41
ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer space - Fierce Biotech
In brief
At the ESMO congress, Lilly reported that its ADC achieved a 79% response rate in the competitive ovarian cancer field.
Why it matters
Not provided in the brief.
Source: news.google.com · news.google.com